Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model

Figure 6

Effect of fenofibrate, metformin, and fenofibrate + metformin on serum antioxidant capacity. Total antioxidant capacity was evaluated in serum from control- (CT-) and diabetic- (DB-) rats subjected to sham- (SH-) or ischemia/reperfusion- (I/R-) myocardial infarction and treated subchronically (14 d) with either vehicle, fenofibrate (Feno, 100 mg/kg), metformin (Metfor, 100 or 300 mg/kg), or Feno (50 mg/kg) + Metfor (50 mg/kg). Data are presented as means ± SEM (–14 rats/group). versus CTSH-Vehicle, versus DBSH-Vehicle, versus CTI/R-Vehicle, and versus DBI/R-Vehicle two-way ANOVA followed by Duncan’s post hoc test.